BRN Discussion Ongoing

Frangipani

Top 20
On a brighter note, BrainChip will be attending four large-scale events later this month:

0BFC5ECA-F5AC-419B-B133-74ED2A35218F.jpeg


We’d already found out about three of the four events prior to the newsletter release. Here is some more info about the fourth one, the Living Planet Symposium in Vienna, organised by ESA.

Douglas McLelland and Gilles Bézard will be representing BrainChip with a talk titled “Event-driven computation and sparse neural network activity deliver low power AI” as part of the session Orbital Intelligence for Earth Observation applications: The edge of AI In Space, chaired by Gabriele Meoni from ESA, who has first-hand experience of AKD1000 cf. https://thestockexchange.com.au/threads/brn-discussion-ongoing.1/post-462334


F800A39C-8C3B-474D-9D3F-5AC3400CF328.jpeg


9A3570AC-1B7C-45EE-B7ED-AAA509CC5510.jpeg
F4948702-3A68-4404-A7CC-F0BCDFFA3C08.jpeg
42DF16AF-3738-43F2-B088-320D4777E0DD.jpeg
46B6117F-D92B-4762-83AF-9EE7E4F03BD7.jpeg
ED758651-27BC-48E0-BB66-344C1BC0B6F7.jpeg
01AC13C7-5497-4E09-9484-9748C2364C46.jpeg
 
  • Like
  • Love
Reactions: 25 users

Frangipani

Top 20
This is how I have generally viewed shares on ASX and suspect that will be the FPO on that chart you posted.

Ordinary shares are the most common type of shares and the full name is fully paid ordinary share or FPO. You may see this abbreviation after the name of the share when you search on your broker's website. Generally, when investors talk about shares, you can assume that they mean ordinary shares.


Thank’s for your reply, @Fullmoonfever!

So the abbreviation FPO in the the stock market context can apparently mean two completely different things, then. 🤪

But why is there no actual chart 📈📉 to be seen and instead the share price is said to be “$null” instead of Friday’s ASX closing price? 🤔
 
  • Like
Reactions: 5 users

CHIPS

Regular
Like many of us BRN shareholders, I received the monthly email newsletter in my inbox today, and it really makes you wonder whether its first paragraph includes some kind of GenAI hallucination when it says:


View attachment 86420
(…)

View attachment 86421


Where and when did this allegedly happen? 🤔

I can neither recall our CMO Steve Brightfield announcing we were now working with Bospar Public Relations & Marketing (first time I heard this agency’s name was in this very newsletter, see above) nor our CFO Ken Scarince announcing Lancaster Grove Capital as “our new agency of record” (?? whatever that is supposed to mean?). Didn’t the info about Lancaster Grove Capital (“Unlocking Potential for Undervalued ASX Companies”) just show up on the BrainChip website the other day without any accompanying announcement on social media channels?


Another claim in the newsletter also had me scratching my head:

View attachment 86422


While it is true that a new Investor Presentation in the form of a PDF document was recently uploaded to that Investor Relations site…





… the Overview section is unfortunately not up to date, with the Frontgrade Gaisler IP license signed in mid-December 2024 missing. Also, VORAGO is still listed as a marquee brand, even though it has mysteriously disappeared from the list of BrainChip customers both on our redesigned website as well as in the latest company presentations (cf. the above May 2025 Investor Update as well as our CTO’s 2025 Embedded Vision Summit presentation).
Not to mention that sentence’s awkward grammar? 🤔



View attachment 86423



In addition, Tony Dawe remains listed as the IR contact person under FAQ, even though on Wednesday, he shared on LinkedIn that from next week on he will no longer be working for our company, as his position has been made redundant.

View attachment 86424


Another thing I noticed on the Investor Relations webpage is that under “Stock”, you can select either BRCHF (OTCQX market in the US) or BRN.


View attachment 86425


I obviously expected to find a similar BRN (ASX) chart to the one found on HC…

View attachment 86426

… so I was rather surprised to discover the following chart instead:

View attachment 86427

What does this chart signify? Does anyone know whether it has been on our IR page for some time already or is it new?


According to Investopedia, FPO means “Follow-on Public Offer”:



Follow-on Public Offer (FPO): Definition and How It Works​


By
JULIA KAGAN

Updated February 03, 2025
Reviewed by
ANDY SMITH
Follow-on Public Offer: An issuance of additional shares made by a company after an initial public offering (IPO).

Investopedia / Laura Porter

What Is a Follow-on Public Offer (FPO)?​

A follow-on public offer (FPO) is the issuance of new shares by a public company after its initial public offering (IPO). As such, FPOs mean that additional shares are offered to the public by companies that are already listed on exchanges. Follow-on public offerings, which are also known as secondary offerings, are generally used by companies to raise additional capital for their growth.

KEY TAKEAWAYS​

  • A follow-on public offer is the additional issuance of a company’s shares after its initial public offering.
  • Companies usually announce FPOs to raise equity or reduce debt.
  • The two main types of FPOs are dilutive, meaning new shares are added, and non-dilutive, meaning existing private shares are sold publicly.
  • An at-the-market offering is a type of FPO by which a company can offer secondary public shares on any given day, usually depending on the prevailing market price, to raise capital.

How Follow-on Public Offers (FPOs) Work​

Public companies can complete an FPO by offering additional shares on the open market. They can also take advantage of an FPO through an offer document. FPOs allow publicly traded companies to raise additional capital by issuing and selling new shares via a stock exchange.

Proceeds from the sale go to the company issuing the stock. Similar to an IPO, companies that want to execute a follow-on public offer must fill out Securities and Exchange Commission (SEC) documents.

This capital can be used for different purposes. Among the primary reasons behind any new issuance of stock is to pay off existing debt or fund growth through:


FAST FACT​

Unlike an FPO, an IPO occurs when a private company issues shares to the public for the very first time through a stock exchange.

Types of Follow-on Public Offers (FPOs)​

There are two main types of follow-on public offers. Dulutive and non-dilutive.


Diluted Follow-on Offering​

The first type of FPO is dilutive to investors, as the company’s board of directors agrees to increase the share float level or the number of shares available. This kind of follow-on public offering seeks to raise money to reduce debt or expand the business, increasing the number of shares outstanding and decreasing the earnings per share (EPS) decrease.

The funds raised during an FPO are most frequently allocated to reduce debt or change a company’s capital structure. The infusion of cash is good for the long-term outlook of the company, and thus, is also good for its shares.

Non-Diluted Follow-on Offering​

The other type of follow-on public offer is non-dilutive. This approach is useful when directors or substantial shareholders sell off privately held shares. Cash proceeds from non-diluted sales go directly to the shareholders placing the stock into the open market.

In many cases, these shareholders are company founders, members of the board of directors, or pre-IPO investors. Since no new shares are issued, the company’s EPS remains unchanged. Non-diluted follow-on offerings are also called secondary market offerings.

At-the-Market (ATM) Offering​

An at-the-market (ATM) offering gives the issuing company the ability to raise capital as needed. If the company is not satisfied with the available price of shares on a given day, it can refrain from offering shares.

ATM offerings are sometimes referred to as controlled equity distributions because of their ability to sell shares into the secondary trading market at the current prevailing price.

Follow-on Public Offerings (FPOs) in the Market​

Follow-on offerings are common in the investment world. They provide an easy way for companies to raise equity that can be used for common purposes. Companies announcing secondary offerings may see their share price fall as a result. Shareholders often react negatively to secondary offerings because they dilute existing shares, and many are introduced below market prices.

Some companies that have completed follow-on public offerings in 2024 include Longboard Pharmaceuticals, with an issuance of 10 million shares valued at $210 million, and Cyngn, with an issuance of 12.42 million shares valued at about $20 million.12

What Are the Benefits of Follow-on Public Offers?​

There are several reasons why a public company will choose to raise more equity. For example, they might use the proceeds to pay off debt and improve their debt-to-value (DTV) ratio, or they can use the funds to improve the company’s growth by financing new projects.

What Are the Advantages of At-the-Market Offerings?​

At-the-market offerings have several advantages, including minimal market impact. Businesses can raise capital quickly without having to announce the offering. ATM offerings are also typically sold for less than traditional follow-on offerings, and they require minimal management involvement.

What Are the Disadvantages of ATM Offerings?​

ATM offerings tend to be smaller than traditional follow-on offerings, so if a business is looking to raise a large amount of capital, this may not be the best method. In addition, the price may fluctuate depending on the market.

The Bottom Line​

An FPO is typically done when the company wants to fund new projects or expansions, pay off debt, or increase its working capital. There are two main types of FPOs, dilutive and non-dilutive. The shares are offered at a fixed price to the public through a book-building process, with the proceeds going directly to the company.

Existing shareholders may also participate in the FPO; either by purchasing additional shares or selling some of their existing ones. FPOs are a way for companies to tap into the capital markets and raise additional funds without taking on debt.




Are they preparing another institutional placement like with Unified Capital Partners or another share purchase plan for existing shareholders?

But then, why don’t the shares of last year’s institutional placement or the share purchase plan offered to existing shareholders with a registered address in Australia or New Zealand (published in July 2024) show up the yearly chart?

Or could this hint at an upcoming non-dilutive FPO, meaning existing private shares by eg. substantial shareholders will be sold publicly?

“Non-Diluted Follow-on Offering

The other type of follow-on public offer is non-dilutive. This approach is useful when directors or substantial shareholders sell off privately held shares. Cash proceeds from non-diluted sales go directly to the shareholders placing the stock into the open market.

In many cases, these shareholders are company founders, members of the board of directors, or pre-IPO investors.
Since no new shares are issued, the company’s EPS remains unchanged. Non-diluted follow-on offerings are also called secondary market offerings.”



Any thoughts on this?


Maybe, only maybe, Steve Brightfield or someone else did make an announcement, but it was not sent by somebody who couldn't care less after losing his job??? And maybe Tony is still mentioned because the new agency will start to work only next month or so? Just some ideas.
 
  • Like
  • Haha
Reactions: 3 users

CHIPS

Regular
Thank’s for your reply, @Fullmoonfever!

So the abbreviation FPO in the the stock market context can apparently mean two completely different things, then. 🤪

But why is there no actual chart 📈📉 to be seen and instead the share price is said to be “$null” instead of Friday’s ASX closing price? 🤔

Maybe Tony forgot to link it to the ASX?

I can't wait to see if the mistakes will stop in the future...
 
  • Like
  • Love
Reactions: 4 users

CHIPS

Regular

The Edge AI Platform That’s Quietly Powering Your Future


:unsure:
 
  • Like
  • Thinking
Reactions: 3 users
It seems competition is coming from everywhere
 

overpup

Regular
Whether you ask me or not… the fact is, the market keeps going for other solutions, even if they can’t do what Akida can. That’s what I was pointing out yesterda
brainchamax
 

manny100

Top 20
Bospar is a good move.
Their website is interesting.
The big positive is the the BOD finally realise that AKIDA and friends (TENNs, Pico) will not sell themselves.
The roadmap was great but all about tech.
We need the see the roadmap that will bring the tech to commercial success.
 
  • Like
  • Love
Reactions: 20 users

DK6161

Regular

DK6161

Regular
Wouldn't surprise me if Steve Brightfield is quitting in the next 6 months. who's next folks?
 
  • Thinking
Reactions: 1 users

manny100

Top 20
Yes we are!
Not advice
What do you see that indicates AKIDA is in Switch 2. Would be great if we are. As a non gamer i can't see any indication.
I have read however that Nintendo are sometimes not 'up front' concerning all its tech specs.
 
  • Like
Reactions: 3 users

Mt09

Regular
What do you see that indicates AKIDA is in Switch 2. Would be great if we are. As a non gamer i can't see any indication.
I have read however that Nintendo are sometimes not 'up front' concerning all its tech specs.
Hot tip..we’re not.
 
  • Like
  • Haha
Reactions: 4 users

manny100

Top 20
  • Like
Reactions: 2 users

Bravo

If ARM was an arm, BRN would be its biceps💪!
If it's being talked about its being worked on.
Wearables for Parkinson's tremor detections obviously far off.
A quiet one not mentioned is concussion in elite contact sports. This will not be long. Elite sporting bodies are facing billions of $$ in claims and the sports need early detection mechanisms and measurement.


This may be what Tata Exlsi is looking at doing here Manny.

Worth keeping an eye on.


ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports Medicine through AI​

Tata_Elxsi_Logo

May 07, 2025, 01:45 ET

BENGALURU, India, May 7, 2025 /PRNewswire/ -- European College of Sport and Exercise Physicians (ECOSEP) and Tata Elxsi have announced a strategic partnership that aims to revolutionise the field of sports and exercise medicine through combining the research excellence and clinical expertise of ECOSEP with Tata Elxsi's AI- and machine learning–driven healthcare solutions and technology capabilities.
The partnership will focus on applying artificial intelligence technologies in areas such as advanced diagnostic tools, personalised treatment plans, predictive analytics for injury prevention, and real-time monitoring of athletes' physical conditions.
This innovative collaboration was initiated by Dr. Pakravan, Vice Chair of ECOSEP, and facilitated by Dr. Malliaropoulos, General Secretary. Speaking on behalf of ECOSEP, Prof. Nicola Maffulli, President, stated: "These are exciting times for how technology and medical science can be brought together to transform personalised care in sports. The long-term vision of Tata Elxsi marries with the aim of ECOSEP to develop and maintain 360° care for athletes and physically active individuals. With the power of Tata Elxsi, ECOSEP shall develop comprehensive packages of care which will help to optimise performance and health. This is a unique opportunity for mutual collaboration, marrying disciplines only apparently different, and allowing close interaction of professionals."
Anup SS, Practice Head – AI and Machine Learning at Tata Elxsi, added: "This collaboration with ECOSEP represents an exciting opportunity to apply AI in ways that directly impact athlete health and performance. By combining clinical insight with advanced data science, we aim to co-create intelligent tools that support early diagnosis, enable real-time decision-making, and personalise care for every athlete. Together, we're paving the way for a new era in sports medicine—one that is smarter, faster, and more human-centric."
The collaboration serves as a stepping stone for future interdisciplinary partnerships aimed at expanding the use of AI in sports and musculoskeletal medicine, and both organisations are committed to advancing the field through research, clinical trials, and the development of AI-driven tools that offer athletes and healthcare providers ground-breaking solutions to achieve optimal outcomes.
Tata Elxsi will join the 9th ECOSEP Congress in Düsseldorf in November 2025 to engage with the clinical community, share early insights, and explore opportunities for collaborative research and innovation.
About Tata Elxsi
Tata Elxsi is a global design and technology services company headquartered in Bangalore. It addresses the healthcare, automotive, broadcast, and communications consumer electronics industries. This is supported by a network of design studios, development centres, and offices worldwide. Tata Elxsi's Healthcare & Life Sciences practice is ISO 13485 certified and collaborates with prominent medical device and pharmaceutical OEMs, as well as technology companies. With a comprehensive services and solutions portfolio, Tata Elxsi adds value at every stage of the customer's product development lifecycle. Recognised as a leader in technology consulting, new product design, development, verification & validation, as well as regulatory compliance services, Tata Elxsi is a trusted name in the industry.

About ECOSEP
European College of Sports and Exercise Physicians (ECOSEP) is a non-profit scientific medical society dedicated to Sports Medicine and Sports Physicians in Europe, with extensive international links and collaborations with other similar specialist societies across the world. The mission of the College is to advance competencies of sports physicians and promote highest standards of specialist care through providing continuing education, research, collaboration with other sports medicine organizations, promoting physical activity and population health, and serving as a source of information to the public. The membership and extensive international reach of ECOSEP puts the College in a unique position to achieve these goals and make an impact on current practice as well as future of the Sport and Exercise Medicine specialty.
For more information and also to learn more about our highly popular biennial congresses please visit: https://ecosep.eu/

rt.gif

 
Last edited:
  • Like
  • Fire
  • Love
Reactions: 24 users
  • Haha
  • Like
Reactions: 3 users
  • Like
  • Fire
Reactions: 3 users
  • Fire
  • Like
Reactions: 2 users
Sean made his comment about 9 million this year, which we don't know the details of so is nintendo apart of this 🤔. Will we ever know since the deal is IP only with Megachip
 
Last edited:
  • Like
Reactions: 2 users
Sean made his comment about 9 million this year, which we don't know the details of so is nintendo apart of this 🤔.
this 9 mil doesnt include ip revenue. it is for new contracts
 
  • Like
  • Fire
Reactions: 4 users
Top Bottom